HNPOLY(SZ:300630) Xin Lang Cai Jing·2025-12-23 02:51Core Viewpoint - The article discusses the significant legal developments regarding investor claims against Puli Pharmaceutical (300630) due to false statements made by the company, leading to a court ruling in favor of investors [1][3]. Financial Misstatements - Puli Pharmaceutical falsely reported sales revenue and profits by fabricating sales of finished and raw pharmaceutical products from 2021 to 2022. In 2021, the company overstated revenue by 436,606,838.34 yuan, which accounted for 28.94% of the reported revenue, and overstated profits by 308,018,435.49 yuan, representing 65.88% of the total reported profit [4][5]. - In 2022, the company overstated revenue by 456,639,341.72 yuan, which was 25.28% of the reported revenue, and overstated profits by 387,417,257.52 yuan, making up 88.27% of the total reported profit [4][5]. Additional Revenue Miscalculations - The company also miscalculated revenue from non-controlling trade activities, leading to an additional overstatement of 77,997,346.38 yuan in 2021 (5.17% of reported revenue) and 59,259,735.84 yuan in 2022 (3.28% of reported revenue) [2][6]. Legal Proceedings - The law firm Shanghai Jiucheng, led by attorney Xu Feng, is actively pursuing further claims and has already achieved a favorable ruling for investors in a recent case. Investors who purchased Puli Pharmaceutical shares between April 26, 2022, and April 17, 2024, are eligible to file claims [3][6].